Reimbursement of Dexcom CGM Technology for Patients with Type 1 and Type 2 Insulin-Dependent Diabetes is Now Available in Germany

USA - English

• USA - Deutsch

SAN DIEGO and EDINBURGH, Scotland, Sept. 7, 2016 /PRNewswire/ -- Dexcom, Inc., (NASDAQ:DXCM), announced that Germany's Federal Joint Committee (G-BA) will provide reimbursement for Dexcom's Continuous Glucose Monitoring (CGM) Systems for patients with insulin-dependent type 1 and type 2 diabetes. The policy change was approved by Germany's Ministry of Health and has now been initiated.

This decision by the G-BA will open the door for many patients to benefit from the advanced CGM technology and help them gain better control of their diabetes.  The new reimbursement policy in Germany only covers technologies that provide alarms and alerts about glucose levels – including the Dexcom CGM System.

"We are thrilled that Dexcom CGM Systems are now accessible and affordable to patients throughout Germany," said Kevin Sayer, President and Chief Executive Officer of Dexcom. "This ground-breaking technology plays a vital role for people with diabetes who are insulin-dependent, allowing them to self-monitor their condition, manage their glucose levels and reduce risk of severe hyper or hypoglycemic events."

The Dexcom G5^® Mobile CGM System and Dexcom G4^® PLATINUM will be included among the CGM devices that will be reimbursed by Germany's Medical Department of the Central Federal Association of Health Insurance Funds. With 288 glucose readings per day, patients using the Dexcom G5 Mobile CGM System can see their glucose levels and make treatment decisions based on the speed and direction of their readings.¹ It also gives patients the added convenience of seeing their readings directly on their mobile device.² G5 Mobile allows patients to share their glucose readings with up to five friends and family, which provides an additional layer of support for patients.

"This is a major win for patients with diabetes in Germany," said Rudolf Messer, MD, Country Manager, Germany. "Before the new ruling took effect, Germany's strict reimbursement policies prevented many people with diabetes from benefitting from CGM, so only a small subset of the insulin-dependent diabetic population in Germany had access to this important and potentially life-saving technology. Now countless people with diabetes, along with their family members and loved ones, will have access to innovative, quality tools to help manage their condition."

Germany is the single largest market in Europe for type 1 and type 2 diabetes, with nearly 6.6 million people living with the disease, according to the International Diabetes Federation.³

About Dexcom, Inc.
Dexcom, Inc., headquartered in San Diego, California, USA, is dedicated to helping people better manage their diabetes by developing and marketing continuous glucose monitoring (CGM) products and tools for adult and pediatric patients.  With exceptional performance, patient comfort and lifestyle flexibility at the heart of its technology, users have consistently ranked Dexcom highest in customer satisfaction and loyalty*. For more information on the Dexcom CGM, visit www.dexcom.com.

*dQ&A patient surveys, 2009-2016

Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements that are not purely historical regarding Dexcom's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to the intended use and technical specifications of the CGM products, the potential impact on outcomes associated with diabetes care.  Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from Dexcom's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: the inability to successfully development new products and obtain regulatory approval; a lack of acceptance in the marketplace by physicians and patients; the inability to manufacture products in commercial quantities at an acceptable cost; possible delays in the company's development programs; the inability of patients to receive reimbursement from third-party payors; and inadequate financial and other resources.  Certain of these risks and uncertainties, in addition to other risks, are more fully described in the section entitled "Risk Factors" in Dexcom's Annual Report on Form 10-K, its most recent Quarterly Report on Form 10-Q, and its other reports filed with the Securities and Exchange Commission.

MEDIA CONTACT:
Caren Begun, 856-424-2023
To view multimedia assets, please visit: http://www.dexcom.com/media

INVESTOR CONTACT:
Steven Pacelli, 858-200-0200

References

1. Dexcom G5 Mobile Continuous Glucose Monitoring System, User's Guide, 2015
2. For a list of compatible smartphones, visit Dexcom.com/compatibility
3. International Diabetes Federation. Diabetes in Germany. http://www.idf.org/membership/eur/germany. Accessed August 25, 2016.

Logo - http://photos.prnewswire.com/prnh/20150811/257482LOGO

SOURCE Dexcom, Inc.

Related Links

http://www.dexcom.com